Loading…
Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial
We performed adoptive immunotherapy (AIT)with tumor-associated lymphocytes (TALs) in combination with chemotherapy in patients with advanced-stage gastric cancer in a randomized controlled study and investigated whether or not an improved survival effect is observed with AIT. Forty-four consecutive...
Saved in:
| Published in: | Clinical cancer research 2002-06, Vol.8 (6), p.1767-1771 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 1771 |
| container_issue | 6 |
| container_start_page | 1767 |
| container_title | Clinical cancer research |
| container_volume | 8 |
| creator | KONO, Koji TAKAHASHI, Akihiro ICHIHARA, Fumiko AMEMIYA, Hideki IIZUKA, Hidehiko FUJII, Hideki SEKIKAWA, Takayoshi MATSUMOTO, Yoshiro |
| description | We performed adoptive immunotherapy (AIT)with tumor-associated lymphocytes (TALs) in combination with chemotherapy in patients with advanced-stage gastric cancer in a randomized controlled study and investigated whether or not an improved survival effect is observed with AIT.
Forty-four consecutive patients with stage IV gastric cancer [staged according to the International Union against Cancer classification] were prospectively assigned to the control group (chemotherapy alone) or the AIT group (AIT plus chemotherapy). Patients in the AIT group received an adoptive transfer of cultured TALs in combination with low-dose cisplatinum/5-fluorouracil chemotherapy, whereas patients in the control group received chemotherapy alone.
The 50% survival rates were 11.5 and 8.3 months in the AIT and control groups, respectively. The overall survival of patients in the AIT group was significantly better than that of patients in the control group, as analyzed by the log-rank test (P < 0.05). Multivariate analysis with Cox's proportional hazards model revealed that AIT provided an independent prognostic factor, indicating that AIT influenced patient survival in a positive manner.
AIT with TALs in combination with chemotherapy was effective in prolonging survival in patients with stage IV gastric cancer. |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71805551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71805551</sourcerecordid><originalsourceid>FETCH-LOGICAL-p237t-94d15600055a913742c769e4e45a712e411189360198ee2b83f996524a49fbd33</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRSMEoqXwC8gb2EXy2wm7quIlVYIFrKup47RGiR1spyh8BZ9MoEWsZqR7dK5mjrIpEULljEpxPO5YFTnmjE6ysxjfMCacYH6aTQjFEksiptnXc_Ab52OyGkW7cba2Gpw2yNcIKt8luzPItm3vfNqaAN2APmzaotS3PuQQo9cWkqlQM7Td1ushmYisQx0ka1yKexqq3Y-0QhuIKYxVvx3hBs1RAFf51n6O4ZhAc56d1NBEc3GYs-z17vZl8ZAvn-4fF_Nl3lGmUl7yigiJMRYCSsIUp1rJ0nDDBShCDSeEFCWTmJSFMXRdsLospaAceFmvK8Zm2fXe2wX_3puYVq2N2jQNOOP7uFKkGN2CjODlAezXralWXbAthGH198MRuDoAEDU09XiRtvGfYwpjriT7Bs02fak</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71805551</pqid></control><display><type>article</type><title>Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial</title><source>Freely Accessible Science Journals - check A-Z of ejournals</source><creator>KONO, Koji ; TAKAHASHI, Akihiro ; ICHIHARA, Fumiko ; AMEMIYA, Hideki ; IIZUKA, Hidehiko ; FUJII, Hideki ; SEKIKAWA, Takayoshi ; MATSUMOTO, Yoshiro</creator><creatorcontrib>KONO, Koji ; TAKAHASHI, Akihiro ; ICHIHARA, Fumiko ; AMEMIYA, Hideki ; IIZUKA, Hidehiko ; FUJII, Hideki ; SEKIKAWA, Takayoshi ; MATSUMOTO, Yoshiro</creatorcontrib><description>We performed adoptive immunotherapy (AIT)with tumor-associated lymphocytes (TALs) in combination with chemotherapy in patients with advanced-stage gastric cancer in a randomized controlled study and investigated whether or not an improved survival effect is observed with AIT.
Forty-four consecutive patients with stage IV gastric cancer [staged according to the International Union against Cancer classification] were prospectively assigned to the control group (chemotherapy alone) or the AIT group (AIT plus chemotherapy). Patients in the AIT group received an adoptive transfer of cultured TALs in combination with low-dose cisplatinum/5-fluorouracil chemotherapy, whereas patients in the control group received chemotherapy alone.
The 50% survival rates were 11.5 and 8.3 months in the AIT and control groups, respectively. The overall survival of patients in the AIT group was significantly better than that of patients in the control group, as analyzed by the log-rank test (P < 0.05). Multivariate analysis with Cox's proportional hazards model revealed that AIT provided an independent prognostic factor, indicating that AIT influenced patient survival in a positive manner.
AIT with TALs in combination with chemotherapy was effective in prolonging survival in patients with stage IV gastric cancer.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 12060615</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Aged ; Antigens, CD - immunology ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Cisplatin - administration & dosage ; Combined Modality Therapy ; Female ; Fluorouracil - administration & dosage ; Humans ; Immunotherapy, Adoptive ; Lymphatic Metastasis - pathology ; Lymphocytes, Tumor-Infiltrating - immunology ; Male ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Pharmacology. Drug treatments ; Prognosis ; Prospective Studies ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Stomach Neoplasms - therapy ; Survival Rate ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>Clinical cancer research, 2002-06, Vol.8 (6), p.1767-1771</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13700476$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12060615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KONO, Koji</creatorcontrib><creatorcontrib>TAKAHASHI, Akihiro</creatorcontrib><creatorcontrib>ICHIHARA, Fumiko</creatorcontrib><creatorcontrib>AMEMIYA, Hideki</creatorcontrib><creatorcontrib>IIZUKA, Hidehiko</creatorcontrib><creatorcontrib>FUJII, Hideki</creatorcontrib><creatorcontrib>SEKIKAWA, Takayoshi</creatorcontrib><creatorcontrib>MATSUMOTO, Yoshiro</creatorcontrib><title>Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>We performed adoptive immunotherapy (AIT)with tumor-associated lymphocytes (TALs) in combination with chemotherapy in patients with advanced-stage gastric cancer in a randomized controlled study and investigated whether or not an improved survival effect is observed with AIT.
Forty-four consecutive patients with stage IV gastric cancer [staged according to the International Union against Cancer classification] were prospectively assigned to the control group (chemotherapy alone) or the AIT group (AIT plus chemotherapy). Patients in the AIT group received an adoptive transfer of cultured TALs in combination with low-dose cisplatinum/5-fluorouracil chemotherapy, whereas patients in the control group received chemotherapy alone.
The 50% survival rates were 11.5 and 8.3 months in the AIT and control groups, respectively. The overall survival of patients in the AIT group was significantly better than that of patients in the control group, as analyzed by the log-rank test (P < 0.05). Multivariate analysis with Cox's proportional hazards model revealed that AIT provided an independent prognostic factor, indicating that AIT influenced patient survival in a positive manner.
AIT with TALs in combination with chemotherapy was effective in prolonging survival in patients with stage IV gastric cancer.</description><subject>Aged</subject><subject>Antigens, CD - immunology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive</subject><subject>Lymphatic Metastasis - pathology</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - therapy</subject><subject>Survival Rate</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpFkMtOwzAQRSMEoqXwC8gb2EXy2wm7quIlVYIFrKup47RGiR1spyh8BZ9MoEWsZqR7dK5mjrIpEULljEpxPO5YFTnmjE6ysxjfMCacYH6aTQjFEksiptnXc_Ab52OyGkW7cba2Gpw2yNcIKt8luzPItm3vfNqaAN2APmzaotS3PuQQo9cWkqlQM7Td1ushmYisQx0ka1yKexqq3Y-0QhuIKYxVvx3hBs1RAFf51n6O4ZhAc56d1NBEc3GYs-z17vZl8ZAvn-4fF_Nl3lGmUl7yigiJMRYCSsIUp1rJ0nDDBShCDSeEFCWTmJSFMXRdsLospaAceFmvK8Zm2fXe2wX_3puYVq2N2jQNOOP7uFKkGN2CjODlAezXralWXbAthGH198MRuDoAEDU09XiRtvGfYwpjriT7Bs02fak</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>KONO, Koji</creator><creator>TAKAHASHI, Akihiro</creator><creator>ICHIHARA, Fumiko</creator><creator>AMEMIYA, Hideki</creator><creator>IIZUKA, Hidehiko</creator><creator>FUJII, Hideki</creator><creator>SEKIKAWA, Takayoshi</creator><creator>MATSUMOTO, Yoshiro</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20020601</creationdate><title>Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial</title><author>KONO, Koji ; TAKAHASHI, Akihiro ; ICHIHARA, Fumiko ; AMEMIYA, Hideki ; IIZUKA, Hidehiko ; FUJII, Hideki ; SEKIKAWA, Takayoshi ; MATSUMOTO, Yoshiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p237t-94d15600055a913742c769e4e45a712e411189360198ee2b83f996524a49fbd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Antigens, CD - immunology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive</topic><topic>Lymphatic Metastasis - pathology</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - therapy</topic><topic>Survival Rate</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KONO, Koji</creatorcontrib><creatorcontrib>TAKAHASHI, Akihiro</creatorcontrib><creatorcontrib>ICHIHARA, Fumiko</creatorcontrib><creatorcontrib>AMEMIYA, Hideki</creatorcontrib><creatorcontrib>IIZUKA, Hidehiko</creatorcontrib><creatorcontrib>FUJII, Hideki</creatorcontrib><creatorcontrib>SEKIKAWA, Takayoshi</creatorcontrib><creatorcontrib>MATSUMOTO, Yoshiro</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KONO, Koji</au><au>TAKAHASHI, Akihiro</au><au>ICHIHARA, Fumiko</au><au>AMEMIYA, Hideki</au><au>IIZUKA, Hidehiko</au><au>FUJII, Hideki</au><au>SEKIKAWA, Takayoshi</au><au>MATSUMOTO, Yoshiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>8</volume><issue>6</issue><spage>1767</spage><epage>1771</epage><pages>1767-1771</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>We performed adoptive immunotherapy (AIT)with tumor-associated lymphocytes (TALs) in combination with chemotherapy in patients with advanced-stage gastric cancer in a randomized controlled study and investigated whether or not an improved survival effect is observed with AIT.
Forty-four consecutive patients with stage IV gastric cancer [staged according to the International Union against Cancer classification] were prospectively assigned to the control group (chemotherapy alone) or the AIT group (AIT plus chemotherapy). Patients in the AIT group received an adoptive transfer of cultured TALs in combination with low-dose cisplatinum/5-fluorouracil chemotherapy, whereas patients in the control group received chemotherapy alone.
The 50% survival rates were 11.5 and 8.3 months in the AIT and control groups, respectively. The overall survival of patients in the AIT group was significantly better than that of patients in the control group, as analyzed by the log-rank test (P < 0.05). Multivariate analysis with Cox's proportional hazards model revealed that AIT provided an independent prognostic factor, indicating that AIT influenced patient survival in a positive manner.
AIT with TALs in combination with chemotherapy was effective in prolonging survival in patients with stage IV gastric cancer.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>12060615</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2002-06, Vol.8 (6), p.1767-1771 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71805551 |
| source | Freely Accessible Science Journals - check A-Z of ejournals |
| subjects | Aged Antigens, CD - immunology Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Cisplatin - administration & dosage Combined Modality Therapy Female Fluorouracil - administration & dosage Humans Immunotherapy, Adoptive Lymphatic Metastasis - pathology Lymphocytes, Tumor-Infiltrating - immunology Male Medical sciences Middle Aged Neoplasm Staging Pharmacology. Drug treatments Prognosis Prospective Studies Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach Neoplasms - therapy Survival Rate Tumor Necrosis Factor-alpha - metabolism |
| title | Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A24%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20adoptive%20immunotherapy%20with%20tumor-associated%20lymphocytes%20in%20patients%20with%20advanced%20gastric%20cancer:%20A%20randomized%20trial&rft.jtitle=Clinical%20cancer%20research&rft.au=KONO,%20Koji&rft.date=2002-06-01&rft.volume=8&rft.issue=6&rft.spage=1767&rft.epage=1771&rft.pages=1767-1771&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71805551%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p237t-94d15600055a913742c769e4e45a712e411189360198ee2b83f996524a49fbd33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71805551&rft_id=info:pmid/12060615&rfr_iscdi=true |